NKTR

Nektar Therapeutics

Price

$76.08

return (12m)

184.73%

p/e

-15.59

p/bv

2.71

DIVIDEND YIELD

0.00%

NKTR price

Nektar Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment NKTR

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

13.55%

3 months

10.94%

1 year

184.73%

2 years

281.35%

5 years

-63.87%

10 years

-71.55%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals NKTR

Valuation

P/E

-15.59

Sector -4.38

Industry -4.38

P/BV

2.71

Sector 2.02

Industry 2.02

P/Revenue (PSR)

44.87

Sector -4.40

Industry -4.40

EV/EBITDA

-53.33

Sector -263.09

Industry -263.09

EV/EBIT

-53.33

Sector -702.90

Industry -702.90

P/EBITDA

-20.12

Sector -4.39

Industry -4.39

P/EBIT

-20.05

Sector -4.73

Industry -4.73

P/Total Assets

2.24

Sector 1.49

Industry 1.49

P/Net Current Assets

4.48

Sector -11.70

Industry -11.70

P/Working Capital

3.66

Sector -3.19

Industry -3.19

EPS

-4.76

Sector -2.14

Industry -2.14

BVPS

27.37

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-326.75%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-326.75%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.01

Sector 0.03

Industry 0.03

Profitability

ROE

-17.40%

Sector -65.14%

Industry -65.14%

ROA

-14.35%

Sector -65.53%

Industry -65.53%

ROIC

-58.09%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

10.42

Sector 2.90

Industry 2.90

Net Debt / EBITDA

20.67

Sector -6.07

Industry -6.07

Net Debt / EBIT

20.67

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.76

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.82

Sector 0.41

Industry 0.41

Liabilities/Assets

0.18

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-11.74%

Sector -

Industry -

5Y Earnings CAGR

-21.40%

Sector -

Industry -

Fundamentals NKTR

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
NKTR Nektar Therapeutics	$76.08	177.36%	0.00%	-15.59	2.71	-17.40%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

NKTR Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Nektar Therapeutics

Nektar Therapeutics

Average Investor10 user rating

4.0 (0 people)

United States

36 years

Founded: 1990

1994

Time since IPO - 32 years

718

Employees

Nektar Therapeutics (United States) is listed on the Nasdaq and has a market capitalization of $2.45 billion, with shareholders equity totaling $903.12 million.

The company employs approximately 718 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Nektar Therapeutics reported $54.59 million in revenue, generating net income of $-157.12 million.

Key financial metrics include a P/E ratio of -15.59, a price-to-book (P/B) ratio of 2.71, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker NKTR.

Market cap

$2.45 billion

Net worth

$903.12 million

$903,120,000.00

Assets

$1.10 billion

$1,095,130,000.00

Total Shares Outstanding

33.00 million

33,000,000

Average Daily Trading Volume

$954.28 Thousand

$954,278.00

Sector

Health Care

Industry

Biotechnology

NKTR

NKTR revenue and profits

Financial Results NKTR

DRAG THE FRAME TO SEE MORE DATA

NKTR cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Nektar Therapeutics (NKTR) today?

A cotação de Nektar Therapeutics (NKTR) hoje está em US$ 76.08, com uma variação de 184.73% em relação ao último ano. A cotação de Nektar Therapeutics (NKTR) iniciou o ano negociando na casa dos US$ 42.28 e hoje está em US$ 76.08. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Nektar Therapeutics (NKTR) e dados de ações do Ibovespa e mercados internacionais.

Quando Nektar Therapeutics (NKTR) paga dividendos?

Nektar Therapeutics (NKTR) não distribuiu dividendos no último ano.

Is Nektar Therapeutics (NKTR) a good investment?

Atualmente, Nektar Therapeutics (NKTR) está cotada a US$ 76.08, com um P/L de -15.59, representando um desvio de -479% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 184.73 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 184.73%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Nektar Therapeutics (NKTR) stock?

Investir em ações de Nektar Therapeutics (NKTR) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Nektar Therapeutics (NKTR) yield today?

A rentabilidade de Nektar Therapeutics (NKTR) foi de 13.55% no último mês, 184.73% no último ano e -63.87% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Nektar Therapeutics (NKTR) hoje, o investimento total seria de US$ 7,608.00, com base na cotação atual de US$ 76.08.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 21,662.26
Em 5 anos: US$ 2,748.77
Em 10 anos: US$ 2,164.48

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

NKTR

Nektar Therapeutics

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment NKTR

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING NKTR WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Nektar Therapeutics

Nektar Therapeutics

United States

36 years

1994

718

PROFIT X PRICE NKTR

Financial Results NKTR

NKTR cash flow

Asset, Revenue and Profit Growth - NKTR

NKTR balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions